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doi:10.1016/j.jfma.2011.07.005Background/Purpose: The subpopulations and functions of tumor-infiltrating lymphocytes
(TILs) from cervical cancer (CC) are altered. Dysfunction of TIL could be partially because
of the inhibition by regulatory T (Treg) cells. FOXP3 is the control gene for the Treg cells.
Methods: We investigated the distribution of TILs and FOXP3þ cells in CC (nZ 10) and cervical
intraepithelial neoplasia (n Z 8) tissues. Double-immunofluorescence and confocal-based
image quantitative microscopic analysis were used to calculate the number of cluster of
differentiation (CD)4þCD25þFOXP3þ Treg cells around the tumor cells.
Results: The CD4þCD25þFOXP3þ phenotype of Treg cells was accumulated around the tumor
cells. CC contains a significantly higher proportion of the FOXP3þ T cells than in cervical in-
traepithelial neoplasia (p < 0.001). Moreover, CC with lymph node metastasis has a higher
proportion of the FOXP3þ T cells than that without lymph node metastasis (p < 0.05).
Conclusion: The increased accumulation of Treg cells suggests that Treg cells are important in
the immunopathogenesis of CC.
Copyright ª 2011, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Immunological tolerance to self-antigens is a tightly regu-
lated process. The immune tolerance is maintained in the
periphery through a variety of mechanisms, including
a population of regulatory T (Treg) cells that actively(H.-N. Ho).
ight ª 2011, Elsevier Taiwan LLCsuppresses the function of autoreactive T cells. These Treg
cells can be identified by their expression of cluster of
differentiation (CD)4, the interleukin (IL)-2 receptor alpha
chain (CD25), and the forkhead family transcription factor
FOXP3. They have the ability to inhibit the development of
autoimmunity when transferred into the appropriate host.
Recent studies have shown that the forkhead/winged-helix
protein FOXP3 is expressed predominantly in Treg, and is
both necessary and sufficient for their development and
function.1 The transcription factor FOXP3 is not only a key& Formosan Medical Association. All rights reserved.
High Treg cells in cervical cancer 581intracellular marker, but is also a crucial developmental
and functional factor for CD4þCD25þ Treg cells.
2e4 During
the past few years, several phenotypically distinct Treg cell
populations have been suggested, and the classic ones are
thymus-derived CD4þCD25þFOXP3þ T cells, Treg cells.
5
Recently, Woo et al6 observed increased numbers of Treg
cells in patients with non-small-cell lung cancer and ovarian
cancer compared with normal blood donors. A higher
frequency of the Treg cells in peripheral blood has been
reported in patients with various cancers, including breast
cancer,7 gastric cancer,8 and hepatocellular carcinoma.9
Cervical cancer (CC) is the second most common cancer
among women worldwide, with 400,000 new cases diag-
nosed each year. Infection by human papillomavirus is
a major risk factor for the development of invasive cervical
carcinoma and its precursor cervical intraepithelial
neoplasia (CIN). CIN I reflects active human papillomavirus
replication and is rarely precancerous, most often resolving
spontaneously. In contrast, CIN II and III represent potential
cancer precursors; more than 12% of CIN III lesions will
progress to cancer, if left untreated.10 The cytotoxic
potential of freshly isolated tumor-infiltrating lymphocytes
(TILs) is usually not expressed.11 Our recent study illus-
trated two possible pathways of cancer immune escape:
down-regulation of perforin and direct blockade of cyto-
toxicity to CC through the engagement of inhibitory natural
killer (NK) receptors (CD94/NKG2A) with their ligand.12
Furthermore, we found that the cancer-derived IL-15
and/or transforming growth factor (TGF)-b could be the
cause of the up-regulation of CD94/NKG2A in TILs, which
does not occur among normal tissue-infiltrating or naive
T lymphocytes.
CD8þ T cells and NK cells use the perforin and granzyme
pathways to kill the infected cells and the tumor cells.
Activated human Treg cells express granzyme A and kill
T cells and antigen-presenting cells through perforin.13
FOXP3 is considered as a T-cell marker and is more
specific than other markers, such as glucocorticoid-induced
tumor necrosis factor receptor (GITR) and Cytotoxic T-
Lymphocyte Antigen-4 or the co-expression of CD4 and
CD25.14 Transfection of FOXP3 gene will convert naive
CD4þCD25 T cells toward a regulatory phenotype in both
mice and humans, and therefore, this molecule represents
a functionally important marker of this Treg-cell pop-
ulation.2,4,15 These observations suggest that the FOXP3 is
presently the most definitive marker of the Treg cells, and
its detection could allow a better understanding of the
mechanisms through which Treg cells are involved in auto-
immune and infectious diseases, as well as transplantation
and tumor immunity. In this study, we focused on the
FOXP3þ cells and their role in CC progression.Materials and methods
Paraffin blocks of human CC (n Z 10) and CIN (n Z 8)
tissues were obtained from the Tissue Bank of National
Taiwan University Hospital. The procedure was approved by
the institutional review board of National Taiwan University
Hospital.
Immunohistochemistry on paraffin sections was per-
formed using the pressure-cooking method of antigenretrieval (20 minutes, citrate buffer, pH 6.5). The slides
were cooled and transferred to phosphate-buffered saline.
Before staining, endogenous peroxidase was blocked. The
slides were incubated overnight at 4C with the primary
antibody and then washed three times with phosphate-
buffered saline. Immunodetection was performed with
biotinylated antimouse secondary antibodies (10 minutes),
followed by peroxidase-labeled streptavidin (DAKO,
Glostrup, Denmark) (10 minutes) and visualized using dia-
minobenzidine chromogen as the substrate (DAKO).
For immunofluorescence staining, tissues were stained
with polyclonal rabbit anti-human-CD3 (DAKO, ready-to-use,
Glostrup, Denmark), mouse anti-human FOXP3 monoclonal
antibody (1:20 dilution, 236A/E7; Abcam, Cambridge, UK),
mouse anti-human CD4 monoclonal antibody (1:20 dilution,
Ab-8; Lab vision, Suffolk, UK), mouse anti-human CD25
monoclonal antibody (1:50 dilution, 4C9; Novocastra, New-
castle, UK), andmouse anti-human CD8monoclonal antibody
(C8/144B; DAKO; ready-to-use), followed by Alexa Fluor
488-conjugated goat antimouse IgG1, Alexa Fluor 594-
conjugated goat antimouse IgG2b, and Alexa Fluor 488-
conjugated donkey antigoat IgG (all 2 mg/mL, Molecular
Probes, Eugene, OR, USA). Sections were then examined
using a confocal laser scanning microscope LSM 510 (Carl
Zeiss, Jena, Germany). An immersion-oil Plan-Apochromat
63/1.4 objective was used. Double fluorescence for green
and red channels was imaged using the excitation of argone
krypton laser at the wavelengths of 488 nm and 543 nm.
Positive cells were quantified by ImagePro Plus software
(Media Cybernetics, Silver Spring, MD, USA) and counted in
20 high power fields using confocal microscopy. Quantifica-
tion was performed on the digitalized image of systematic
randomized selected fields by two independent observers.
Statistical analysis was performed using the SPSS soft-
ware program for Windows (version 12.0; SPSS, Chicago, IL,
USA). The percentage of FOXP3þ/CD3þ cells was compared
by Mann-Whitney U test between CIN and CC. Then the
Kruskal-Wallis test was applied to compare the percentage
of FOXP3þ/CD3þ cells among four groups (CINI/II, CIN III, CC
with lymph node metastasis, and CC without lymph node
metastasis). If the Kruskal-Wallis test is positive (p < 0.05)
then Mann-Whitney test was used for pairwise comparison
of subgroups. A p value <0.05 was considered as signifi-
cantly different.Results
Immunohistochemistry showed that in these CC specimens,
most of the CD4, CD8, and FOXP3-expressing cells were
located around the tumor sites (Fig. 1A). This result indi-
cates that TILs cannot migrate into tumor cells, and remain
outside the tumor cells instead. In CIN, the infiltration of
some CD4þ and CD8þ cells into epithelial cells was
observed. However, few FOXP3-expressing cells had infil-
trated into epithelial cells (Fig. 1B).
In individuals with malignant CC (n Z 10), we identified
a substantial population of CD4þCD25þ T cells by immuno-
fluorescence staining in paraffin-embedded tissue sections.
Consistent with the above observation of the FOXP3þ cells,
CD4þCD25þ T cells in the tumor environment indicated that
CD4þCD25þ cells preferentially accumulate around the
Figure 1. Paraffin-embedded tissue sections were stained with antibodies to human CD4, CD8, and FOXP3 from patients with (A)
cervical cancer and (B) cervical intraepithelial neoplasia. Infiltrating cells of positive staining are indicated by black arrows.
Original magnification, 100. E Z epithelial cells; T Z tumor cells.
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staining analysis, we showed that the FOXP3þ cells expressed
CD4 and a large amount of CD25. As shown in Fig. 2B, over
95% of the FOXP3-expressing cells were CD4þ T cells, and up
to 75% of the FOXP3-expressing cells were CD25þFOXP3þ.
This result indicates that most of the FOXP3þ cells are
CD4þCD25þFOXP3þ cells. In summary, we showed that the
CD4þCD25þFOXP3þ phenotype of tumor-associated Treg cells
had accumulated in the tumor environment, especially
around the tumor cells.
In immunofluorescence staining analysis, there were
FOXP3þCD25þ cells in close contact with the CD8þ T cells.
FOXP3þ T cells in the tumor mass were in proximity to the
infiltrating CD8þ T cells, suggesting that physical contactbetween CD4þCD25þ T cells and CD8þ cytotoxic T cells
might mediate regulatory functions. Therefore, cell-cell
contact mediated suppression might be necessary for the
CD4þCD25þ Treg cells. Close contact between FOXP3
þCD25þ
cells and CD8þ T cells suggests that tumor-associated
FOXP3þ T cells might be involved in the dysfunction of
the CD8þ cytotoxic T cells in tumors through cell-cell
contact mediated suppression.
We found that CC contained a significantly higher
proportion of the FOXP3þ T cells than in CIN (p < 0.001,
Fig. 3A). Furthermore, we classified the specimens into four
groups: CIN I/II, CIN III, CC without lymph node metastasis,
and CC with lymph node metastasis. The percentage of
the FOXP3þCD3þ T cells in the CD3þ T cells was higher in
Figure 2. (A) CD4þCD25þ cells preferentially accumulate around the tumor cells. Cervical cancer tissue sections were analyzed
by immunofluorescence multicolor staining and examined by confocal microscopy. The nucleus was stained by DAPI. (B) FOXP3þ
T cells in a cervical tumor mass. Tissues were stained with antibodies to human FOXP3, human CD25 and CD4. All of the FOXP3þ
T cells express CD4, and most strongly express CD25 (n Z 3 for each). The box showed original magnification, 630. DAPI Z 40-6-
diamidine-2-phenyl indole; T Z tumor cells.
Figure 3. (A) Cervical cancer tissues contain a higher
percentage of FOXP3þ cells in the T cell population than in
cervical intraepithelial neoplasia. (B) In later stages of cervical
cancer, patients have a higher proportion of the FOXP3þ T cell
infiltration. Representative samples are shown. )p < 0.05,
))p < 0.001 by Mann-Whitney U test; CC LN() Z cervical
cancer patients without lymph node metastasis; CC LN(þ) Z
cervical cancer patients with lymph node metastasis;
CIN Z cervical intraepithelial neoplasm.
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metastasis had more FOXP3þ T cells than CIN III or CIN I/II
(both p Z 0.014, Fig. 3B). Similarly, CC with lymph node
metastasis had more FOXP3þ T cells than in CIN III or CIN I/II
(both p Z 0.014). Furthermore, CC with lymph node
metastasis had more FOXP3þ T cells than in CC without
lymph node metastasis (p Z 0.045).
Discussion
T cells or CD3þ T lymphocytes belong to a group of white
blood cells known as lymphocytes, and play a central role in
cell-mediated immunity. Treg cells, particularly CD4
þCD25þ
Treg cells, are key mediators of peripheral tolerance.
16
Engendering strong antitumor immunity may thus involve
breaking Treg-mediated peripheral tolerance to tumor-
associated antigens. Consistent with this concept, experi-
mental depletion of Treg cells in mice with tumors improves
immune-mediated tumor clearance and enhances theresponse to immune-based therapy.17,18 Recently, a study
used systemic application of agonistic anti-GITR antibodies,
and they demonstrated inactivated Treg cells, increased
intratumoral invasion of the CD8þ T cells and complete
tumor eradication in 70% of treated animals.19
Humans with cancer have increased number of peripher-
ally circulating tumor Treg cells.
6,7 Curiel et al20 showed that
the Treg cells in human ovarian cancers express intracellular
Cytotoxic T-Lymphocyte Antigen-4, GITR and FOXP3, inhibit
tumor-assciated antigens-specific immunity, and contribute
to tumor growth.20 This demonstrated that the human Treg
cells have an important immunopathological role in human
cancer by suppressing endogenous tumor-assciated antigens-
specific T cell immunity. Furthermore, this study further
linked this immunopathological role to clinical outcomes, by
demonstrating that there is an inverse correlation between
the tumor Treg cell content and patient survival.
Consistent with the observation in human ovarian
cancer,20 our data show that this phenomenon can also be
shown in CC. We found a significant trend toward a higher
accumulation of the Treg cells around the cervical tumor
mass in advanced tumor stages. Therefore, Treg cells seem
to exist preferentially around the tumor mass. This implies
that Treg cell-mediated immunosuppression is a crucial
tumor “immunoediting” mechanism and the main obstacle
of successful tumor immunotherapy.
An important question is "Where do these Treg cells come
from?" By focusing on the tumor microenvironmentdthe
active battlefront between tumors and the host immune
systemdthe sources of Treg cells in tumors can be summa-
rized as follows: trafficking, differentiation, expansion,
and conversion. Natural Treg cells differentiate in the
thymus and migrate to peripheral tissue. The mouse thymus
produces Treg cells as a separate lineage that expresses
FOXP3. Because tumor-associated Treg cells express FOXP3
mRNA and protein, it is possible that these cells traffic to
tumors from the thymus, bone marrow, lymph nodes, and
peripheral blood under the influence of tumor microenvi-
ronmental chemokine ligand 22.20
Treg cells can be induced and differentiated in the
periphery such as in the tumor microenvironment. Tumor
environmental factors, such as vascular endothelial growth
factor, IL-10, and TGF-b, suppress dendritic cell (DC) differ-
entiation and function resulting in immature and/or partially
differentiated DCs. Tumors convert DCs into TGF-b-express-
ing immature myeloid DCs that are capable of promoting
Treg-cell proliferation.
21 On the other hand, normal mature
DCs stimulate the in vivo expansion of self-antigen-specific
Treg cells in mice.
22,23 As a result, thymus-derived Treg cells
in the tumor microenvironment might clonally expand the
following stimulation by tumor-associated DCs.
Based on our previous studies, CC cells express TGF-b
to drive the tumor-encountered T cells toward Th2/Tc2
polarity.24 TGF-b is abundantly expressed in most, if not all,
cancer cells, but is not or only very weakly expressed in
normal cervical epithelial or stromal cells.12 Therefore, we
consider that Treg accumulation in CC is due to TGF-b-
mediated conversion from the CD4þCD25 T cells. Further-
more, a recent study also showed that, using mice with
a reporter introduced into the endogenous Foxp3 locus, IL-6,
an acute phase protein induced during inflammation,
completely inhibits the generation of FOXP3þ Treg cells
High Treg cells in cervical cancer 585induced by TGF-b.25 This inhibition of Treg development
by different cytokines demonstrates that the development of
the FOXP3þ Treg cells may be affected by multiple cytokines.
Our previous data, using flow cytometry and kinetic
cytotoxicity assays, demonstrated retrained CD8þ T
lymphocyte cytotoxicity.12 A recent report showed that the
location of immune cells within human colorectal tumors
could predict clinical outcome.26 Therefore, the relative
microenvironmental positions among these immune-
modulating and CC cells need further verification. In the
present study, we showed that TILs within tumor sites are
located around the tumor cells. The possible reason to
explain this distribution is tumor immune privilege. One of
the many mechanisms adopted by tumors to destroy
immune surveillance is to “counterattack” TILs. Tumors
might establish an immune-privileged site to protect
themselves from the immune response. Numerous studies
have demonstrated FasL expression in many diverse types
of human cancer, where it may contribute to tumor immune
privilege.27 Two independent studies found that the tumor-
expressed FasL was significantly associated with a local
decrease in the number of in situ TILs in human esophageal
cancers.28,29 There was a consistent local decrease in the
number of TILs in FasLþ tumor islands relative to matched
FasL tumor islands within every tumor examined. The
local decrease in TILs was concomitant with a consistent
increase in apoptosis among TILs.28
The accumulation of Treg cells in tumors predicts
a marked severity in cervical dysplasia, providing the
“smoking gun” that links the Treg cells and the immuno-
pathogenesis of human cancer. Taken together, these data
might be helpful for developing immune-boosting strate-
gies based on ridding the cancer patient of this cell
population.
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